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A B S T R A C T
Background: Pregnant women may experience constipation for the first time or their existing constipation symptoms increase in 
severity during pregnancy. Aim: To compare the effect of progesterone versus diet modification in the treatment of constipation 
during pregnancy. Subjects and Methods: Women aged ≥18 years with functional constipation according to the Rome III 
criteria from obstetrics outpatients’ clinic and midwife practices included in this study. Participants divided into two groups; 
control group managed with diet modifications and study group pregnant women with threatened miscarriage and advised 
to take vaginal progesterone ≥1 week. Participants completed a nonvalidated questionnaire created by the authors during the 
whole week before intake of progesterone or diet modifications and after treatment phase. Independent Student’s t-test and 
Chi-square (2) test were used for statistical analysis to compare between two studied groups. Primary outcome measures; 
change in defecation frequency. Results: Sensation of anorectal obstruction and sensation of incomplete evacuation were 
significantly less in Group B (progesterone therapy) compared to Group A (diet modification) (54% [154/281] and 62.98% [177/281] 
vs. 89.76% [614/684] and 91.08% [623/684], respectively) (P = 0.04 and 0.03, respectively). Straining during defecation and manual 
maneuvers to facilitate evacuation were significantly less in Group B compared to Group A (63.7% [179/281] and 19.9% [56/281] 
vs. 94.59% [647/684] and 86.54% [592/684], respectively) (P < 0.01 and 0.02, respectively). Episodes of abdominal pain and 
presence of reflux episodes were also significantly less in Group B compared to Group A (18.5% [52/281] and 17.43% [49/281] 
vs. 84.11% [589/684] and 75% [513/684], respectively) (P = 0.01 and 0.03, respectively). Conclusions: Estrogen, rather than 
progesterone, may be a detrimental factor of constipation during pregnancy via decreased bowel movement. Progesterone 
therapy seems to be effective in the treatment of functional constipation during pregnancy. A randomized placebo controlled 
trial is required to confirm the data of this study.
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INTRODUCTION
Constipation is a very common clinical problem.[1] Pregnant 
women may experience constipation for the first time or 
their existing constipation symptoms increase in severity 
during pregnancy.[2]
The reported prevalence of constipation in pregnant 
women varies between 11% and 38% and occurs mostly 
during the third trimester, although symptoms can also 
be present from 12 weeks’ gestation.[3] Constipation due 
to infrequent bowel movements or difficult passage of 
stools is a common cause of painful defecation and fecal 
impaction.[4]
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Constipation usually manifested by straining during 
defecation, lumpy or hard stools, sensation of incomplete 
evacuation or anorectal obstruction, manual maneuvers to 
facilitate defecation, and/or less than three defecations per 
week.[5]
The pathophysiology underlying functional constipation 
is undoubtedly, multifactorial, and not well understood. 
Progressively, rising progesterone and estrogen levels 
have suggested as the cause of constipation during 
pregnancy.[6]
Besides discomfort of constipation symptoms, straining 
during defecating can damage the pudendal nerve 
and impair the supportive function of the pelvic floor 
musculature.[7] Furthermore, disturbed defecation can 
result in the development of uterovaginal prolapse.[8]
Therefore, it is important to recognize the symptoms of 
constipation and treat these complaints in early pregnancy. 
In clinical practice, laxatives and fiber are frequently used. 
Nowadays, there are few effective interventions published 
preventing or treating constipation during pregnancy.[9] 
There is weak evidence that increased fiber intake treating 
or improves constipation during pregnancy.[9] Vazquez 
conducted a systematic review and found that stimulant 
laxatives may be more effective than bulk laxatives in 
improving constipation in pregnancy, although adverse 
effects, such as abdominal pain and diarrhea, could limit 
their use.[10]
In addition, Vazquez found that dietary fiber may improve 
constipation in pregnant women compared with placebo 
and it is not clear whether increasing fluid intake improves 
constipation in pregnancy or not.[10]
Although progesterone has been the hormonal explication 
for many gastrointestinal symptoms that occur in 
pregnancy, including constipation, a recent study suggested 
the possibility that estrogen rather than progesterone 
may be responsible for the delay in gastric emptying and 
constipation in pregnancy.[11]
Oh et al. showed that administration of estrogen-induced 
constipation via a decrease in a bowel movement in mice 
but progesterone did not.[11] Oh et al. conclusion does 
not show agreement with the reports suggesting that 
progesterone is an important risk factor for constipation 
in women.[11-15]
This study designed to compare the effect of progesterone 
versus diet modification in the treatment of constipation 
during pregnancy.
SUBJECTS AND METHODS
A total of 965 pregnant women with chronic constipation 
finally analyzed in this study after informed consent 
and approval of the Local Institute Ethical Committee of 
Maternity Hospital, Sabah area, Kuwait, from April 2012 to 
March 2015 [Figure 1].
Pregnant women <24 weeks with threatened miscarriage 
and functional constipation according to the Rome III 
criteria (lasting for at least 2 weeks with symptom onset 
during pregnancy) included in the study group. The 
presence of singleton pregnancy, with positive fetal heart 
activity, gestational age <24 weeks by date, and confirmed 
by ultrasound.
Functional	constipation	diagnosed	if	there	was	at	least	≥2	
of Rome III criteria; (1) straining during defecations, lumpy 
or hard stools in defecations, sensation of incomplete 
evacuation or anorectal obstruction/blockage, manual 
maneuvers to facilitate defecation for at least 25% of 
defecations, fewer than three defecations per week. (2) Loose 
stools are rarely present without the use of laxatives or 
(3) insufficient criteria for irritable bowel syndrome.
Women with endocrine disorders (hypothyroidism), 
Hirschsprung’s disease, spinal anomalies, anorectal 
pathology, inflammatory bowel disease, previous 
gastrointestinal surgery excluded from this study. In 
addition, women with pregnancy-induced hypertension, 
gestational diabetes mellitus, antepartum hemorrhage 
or placenta previa, women allergic to progesterone 
preparations, women on progesterone therapy for 2 weeks 
before inclusion in this study, multiple gestation, uterine 
anomalies or fetal anomalies or absence of fetal cardiac 
activity also excluded from this study.
All participants completed a nonvalidated questionnaire 
created by the authors about their defecation frequency, 
sensation of incomplete evacuation, sensation of anorectal 
obstruction, straining during defecation, manual maneuvers 
to facilitate defecation during the whole week before 
intake of progesterone, or diet modifications. In addition, 
gastrointestinal symptoms such as abdominal pain, reflux 
episodes, and diarrhea evaluated.
Furthermore, a general medical history and the use of 
medication recorded. Information and education about 
functional constipation given to studied women. Before the 
start of the progesterone treatment, all subjects received 
rectal tap water enema once daily for 3 days to achieve 
rectal disimpaction and to create a homogeneous study 
group. No limitation on the use of tap water enema by our 
Institutional Review Board.[16]
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Participants divided into two groups; control group (684 
women), managed with diet modifications as treatment for 
their constipation by dietitian and study group (281 women) 
who developed threatened miscarriage and advised to take 400 
mg progesterone vaginally (Cyclogest, Actavis, United Kingdom) 
daily	for	≥1	week	each	until	their	bleeding	stopped	[Figure 1].
Diet modification includes increased fiber intake in the form 
of vegetables (carrots, romaine lettuce, broccoli, beetroot, 
and cucumbers) and fruits (apples, peaches, and melons). 
Unpolished rice contains water-soluble fibers; psyllium husk 
is a natural product that contains several types of fiber. 
Plenty of water throughout the day and glass of prune juice 
every morning will prevent constipation.[10]
During the treatment phase, the pregnant women filled 
daily diary containing similar questions as the questionnaire 
used at baseline evaluation. Data from the defecation diary 
summarized into weekly outcomes to be able to compare 
parameters of the study in the studied groups regarding its 
frequency and its difference from baseline.
Medications adverse effects and compliance evaluated at 
baseline and at 2, 4, and 6 weeks after starting progesterone 
therapy or diet modifications.
Primary outcome measures; change in defecation 
frequency. Secondary outcome measures; sensation of 
incomplete evacuation, sensation of anorectal obstruction, 
straining during defecation, manual maneuvers to facilitate 
defecation, abdominal pain, reflux episodes, medications 
adverse effects, and compliance.
Sample size and statistical analysis
Using G*Power software version 3.17 (Heinrich Heine 
Universität; Düsseldorf; Germany) for sample size 
977 women with chronic constipation
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Figure 1: The study course, excluded cases and reasons for exclusion
calculation, setting the α-error probability at 0.05, 
power (1-β error probability) at 0.95%, and effective sample 
size (w) at 0.3. The effective size (w) was calculated as 
follows: w N= /2χ , where 2 is the Chi-square test and 
N is the total sample size.	A	number	of	participants’	≥220	
needed to produce a statistically acceptable figure. Collected 
data were statistically analyzed using Statistical Package for 
Social Sciences; computer software version 18 (Chicago, 
IL, USA). Mean and standard deviation (SD) were used 
to represent numerical variables, while number and 
percentage were used to represent categorical variables. 
Independent Student’s t-test used for numeric parametric 
variables, and 2 test used for categorical variables analysis. 
P < 0.05 was considered statistically significant.
RESULTS
There was no significant difference between two studied 
groups regarding; mean age, parity, weight, body mass 
index, and gestational age at inclusion in this study [Table 1].
There was no significant difference between two studied groups 
regarding,	number	of	women	with	≥3	defecations/weeks	and	
frequency of defecation each week [Table 2].
Table 1: Demographic data of the two studied groups







Age (years) 30.7 (5.3) 32.2 (4.2) 0*
Parity 3 (1.4) 4 (2.1) 1.0*
Weight (kg) 89.6 (7.2) 94.1 (6.7) 0.08*
BMI (kg/m2) 30.4 (4.3) 32.1 (5.3) 0.9*
Gestational age at 
inclusion (weeks)
13.1 (1.03) 14.24 (0.54) 0*
*Nonsignificant difference. Data presented as mean (SD). Statistical analysis done using 
Student’s t-test. BMI=Body mass index, SD=Standard deviation
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Sensation of anorectal obstruction and sensation 
of incomplete evacuation were significantly less in 
Group B (progesterone therapy) compared to Group A 
(diet modification) (54% [154/281] and 62.98% [177/281] 
vs. 89.76% [614/684] and 91.08% [623/684], 
respectively) (P = 0.04 and 0.03, respectively).
Straining during defecation and manual maneuvers 
to facilitate evacuation were significantly less in 
Group B compared to Group A (63.7% [179/281] and 
19.9% [56/281] vs. 94.59% [647/684] and 86.54% [592/684], 
respectively) (P < 0.01 and 0.02, respectively).
Episodes of abdominal pain and the presence of reflux 
episodes were also significantly less in Group B compared 
to Group A (18.5% [52/281] and 17.43% [49/281] vs. 
84.11% [589/684] and 75% [513/684], respectively) (P = 0.01 
and 0.03, respectively) [Table 2].
Two women used rescue medication (Bisacodyl/Dulcolax®); 
one patient used Bisacodyl once in week 1, five times in 
week 2, and daily in week 3 and 4. The second woman 
used Bisacodyl only once in week 4. No side effects 
reported with any medications used during this study. 
The compliance with progesterone therapy and diet 
modification was 100%.
DISCUSSION
Females often affected by constipation than males, especially 
during pregnancy. Although progesterone has been the 
hormonal explication for many gastrointestinal symptoms 
that occur in pregnancy, including constipation, a recent 
study suggested the possibility that estrogen rather than 
progesterone may be responsible for the delay in gastric 
emptying and constipation in pregnancy.[11]
Hence, this study designed to compare the effect of 
progesterone versus diet modification in the treatment of 
constipation during pregnancy.
There is limited evidence that dietary fiber and fluid 
intake improve constipation in pregnant women. 
However, because of health benefits, increase fluid 
intake recommended as one of the first measures to 
relieve constipation. Painful perineum after episiotomy 
and prolonged recumbency after cesarean deliveries can 
aggravate constipation.[6,17]
In clinical practice, laxatives and fiber are frequently used in 
the treatment of constipation during pregnancy. Laxatives 
such as lactulose (synthetic nondigestible sugar Duphlac®, 
Abbott Maidenhead, UK) and Bisacodyl (Dulcolax/Durolax®, 
Boehringer Ingelheim Limited, Bracknell, Berkshire, 
RG12 8YS, UK) have proven to be safe for mother and 
fetus.[18]
Unfortunately, their side effects, such as abdominal pain and 
diarrhea, limit their use.[10] Polyethylene glycol 3350 (PEG, 
GlycoLax/MiraLax®, Kremers Urban Pharmaceuticals, New 
Jersey, USA), based laxatives technically meet the ideal 
criteria for constipation treatment; however, present data 
are insufficient to exclude any adverse effects on the fetus.[19]
To the best of our knowledge, this is the first study 
investigating the use of progesterone in constipated 
pregnant women. Based on the results of this study, 
progesterone could be of additional value in the prevention 
and treatment of constipation in pregnant women. An 
increase in defecation frequency observed during this study 
in progesterone group, but this increase was insignificant. 
Furthermore, sensation of anorectal obstruction, sensation 
of incomplete evacuation, straining during defecation 
manual maneuvers to facilitate evacuation, episodes of 
abdominal pain, and presence of reflux episodes were 
significantly less in Group B (progesterone therapy) 
compared to Group A (diet modification).
Many studies suggested that the findings in men, 
nonpregnant women, elderly, and children are not 
applicable to constipated pregnant women, because of 
differences in pathophysiology and hormone levels during 
pregnancy mainly progesterone.[20,21]
The association of female sex steroid hormones and 
constipation are still not clear. Oh et al. showed that 
Table 2: Treatment outcome of the two studied groups
Variables Group A diet modification (n=684) (%) Group B progesterone therapy (n=281) (%) P, significance
Defecation frequency/week 3.1 (0.8) 6.7 (3.2) 1*
Defecation frequency ≥3 week 152 (22.2) 143 (50.88) 0*
Sensation of anorectal obstruction 614 (89.76) 154 (54) 0.04**
Sensation of incomplete evacuation 623 (91.08) 177 (62.98) 0.03**
Straining during defecation 647 (94.59) 179 (63.7) <0.01**
Manual maneuvers to facilitate defecation 592 (86.54) 56 (19.9) 0.02**
Episodes of abdominal pain 589 (84.11) 52 (18.5) 0.01**
Presence of reflux episodes 513 (75) 49 (17.43) 0.03**
**Significant difference, *Nonsignificant difference. When data presented as mean (SD), statistical analysis done using Student’s t‑test, When data presented as number and percentage, 
statistical analysis done using Chi-square test. SD=Standard deviation
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administration of estrogen-induced constipation via a 
decrease in bowel movement in both male and female mice 
but progesterone did not.[11] This result suggests that estrogen 
rather than progesterone may be a detrimental factor of 
constipation; however, this conclusion does not show 
agreement with some reports suggesting that progesterone 
is an important risk factor for constipation in women, and this 
hypothesis was supported by results indicating that females 
had greater frequency of constipation during pregnancy.[12-15]
A recent study suggested the possibility that estrogen 
rather than progesterone may be responsible for the delay 
in gastric emptying and increase in colonic transit time 
observed in pregnancy.[11]
Parenteral administration of estradiol, the predominant 
estrogen during reproductive years to rats resulted in 
inhibited gastric emptying.[22,23]
On the other hand, female rats treated with progesterone 
did not show a decrease in colon myoelectric signal.[24]
CONCLUSIONS
Estrogen rather than progesterone may be a detrimental 
factor of constipation via decreased bowel movement. 
Progesterone therapy seems to be effective in the treatment 
of functional constipation during pregnancy. A randomized 
placebo controlled trial is required to confirm data of this 
study.
The strength of this study is coming from being the first study 
investigating the use of progesterone in constipated pregnant 
women. In this study, due to the presence of a control group, 
the placebo effect of progesterone excluded and because of 
the controlled design, there is detailed information available 
on the natural course of constipation during pregnancy.
A limitation of this study is the nonvalidated questionnaire 
used at baseline, which could have caused recall bias 
resulting in possible underreporting of defecation frequency 
per week and other defecation-related parameters before 
the study.
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